Abbott India is immune from US tariff woes. Buy for TP ₹40128 (+16%)

Abbott India is immune from US tariff woes. Its core portfolio productivity is highest in industry & will be able to report highest-ever EBITDA margin of 30%+ & sustain ROCE of 45% (highest in industry). It can be valued on par with GSK. TP ₹40128 (+16%) https://rakesh-jhunjhunwala.in/abbo...or-target-price-of-₹40128-16-upside-bob-caps/